Clinical trial NCT00857064: Subjective Well Being of Schizophrenic Patients in Greece
Official title: Subjective Well Being of Schizophrenic Patients in Greece
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia
Keywords: Schizophrenia
antipsychotics
social functioning
subjective well being
Patients suffering from Schizophrenia
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2009-03-06
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Target Group:Patients suffering from Schizophrenia treated in private practice

Brief summary: Non-interventional study aiming to provide data on the subjective effects of antipsychotic medication assessing subjective well-being and global functioning of patients with Schizophrenia under antipsychotic medication. Moreover it aims to assess their adherence to the treatment and will investigate whether there is any correlation of these factors with the clinical condition of these patients.


Eligibility criteria: Inclusion Criteria:

* Provision of written informed consent
* Diagnosis of schizophrenia according to DSM-IV
* The patient must have been prescribed an atypical antipsychotic for at least 4 weeks before the first study visit

Exclusion Criteria:

-

Primary outcomes:
measure: Assessment of Subjective well being
timeFrame: Relative score reported in SWBN scale at the visit. No baseline comparison
measure: Assessment of functioning
timeFrame: Relative score reported in GAF scale at the visit. No baseline comparison
Secondary outcomes:
measure: Assessment of Compliance to therapy
timeFrame: Relative score reported in BARS scale at the visit. No baseline comparison
measure: Assessment of General Psychopathology
timeFrame: Relative score reported in PANNS scale at the visit. No baseline comparison
measure: Assessment of Clinical Condition
timeFrame: Relative score reported in CGIS scale at the visit. No baseline comparison
Other outcomes:
Locations:
city: Agrinio
country: Greece
facility: Research Site
city: Alexsandroupoli
country: Greece
facility: Research Site
city: Argos
country: Greece
facility: Research Site
city: Arta
country: Greece
facility: Research Site
city: Athens
country: Greece
facility: Research Site
city: Crete
country: Greece
facility: Research Site
city: Drama
country: Greece
facility: Research Site
city: Edessa
country: Greece
facility: Research Site
city: Elefsina
country: Greece
facility: Research Site
city: Giannitsa
country: Greece
facility: Research Site
city: Ioannina
country: Greece
facility: Research Site
city: Karditsa
country: Greece
facility: Research Site
city: Katerini
country: Greece
facility: Research Site
city: Kavala
country: Greece
facility: Research Site
city: Kozani
country: Greece
facility: Research Site
city: Larisa
country: Greece
facility: Research Site
city: Patra
country: Greece
facility: Research Site
city: Peiraias
country: Greece
facility: Research Site
city: Preveza
country: Greece
facility: Research Site
city: Rodos
country: Greece
facility: Research Site
city: Serres
country: Greece
facility: Research Site
city: Thessalonica
country: Greece
facility: Research Site
city: Thiva
country: Greece
facility: Research Site
city: Volos
country: Greece
facility: Research Site
Study officials:
affiliation: Sismanoglio Hospital, Psychiatric Department, Greece
name: Errikos Tzempelikos, Dr
role: PRINCIPAL_INVESTIGATOR
References: